fMRI: Brain Activation Patterns in Schizophrenia After Computerized Cognitive Skills Training

Sponsor
Manhattan Psychiatric Center (Other)
Overall Status
Completed
CT.gov ID
NCT00431223
Collaborator
Nathan Kline Institute for Psychiatric Research (Other)
11
1
2
24
0.5

Study Details

Study Description

Brief Summary

This project is a novel exploratory research project to investigate changes in activation patterns of the dorsolateral prefrontal cortex (DLPFC) in inpatients with schizophrenia who received a 12-week computerized cognitive remediation (CRT) program. The hypothesis is that patients receiving CRT will show greater increase in activation patterns in the brain as compared to controls, and the degree of brain activation will correlate with improvements in working memory.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Cognitive remediation therapy
N/A

Detailed Description

Abnormalities in the domains of attention, working memory (WM) and information processing are important features of schizophrenia. There is growing literature that cognitive remediation therapy (CRT) can produce modest improvements in cognitive functioning in schizophrenia, suggesting that systematic efforts at improving cognitive functioning are feasible. Cognitive improvement after CRT may correlate with changes in brain activation patterns in specific areas.

After screening, patients are randomized to a 12 week trial of CRT using COGPACK (Marker Software), or to a 12-week control condition. All patients attend 3 weekly 1-hour laboratory sessions, with 1 discussion session per week.

Patients continue their antipsychotic treatment with a typical or atypical antipsychotic during the CRT and 4 weeks prior to enrollment in the study (Phase A). Following Phase A they receive baseline evaluations, including an cognitive activation task (N-back visual-letter task) while being scanned for fMRI , MATRICS neuropsychological test battery, and psychiatric, social functioning, and symptoms assessment.

Patients then enter Phase B with randomization to control or CRT for 12 weeks (36 laboratory sessions). Upon successful completion of 36 sessions, endpoint evaluations include an N-back task while fMRI scan, MATRICS, psychiatric, and social functional assessments.

All baseline and endpoint fMRI scans are conducted at the Center for Advanced Brain Imaging (CABI) at Nathan Kline Institute for Psychiatric Research.

Study Design

Study Type:
Interventional
Actual Enrollment :
11 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Does Computerized Cognitive Skills Training Change Brain Activation Patterns in Schizophrenia?
Study Start Date :
Sep 1, 2006
Actual Primary Completion Date :
Sep 1, 2008
Actual Study Completion Date :
Sep 1, 2008

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Active Group

7 patients were assigned to Cognitive Remediation Therapy..

Behavioral: Cognitive remediation therapy
36 sessions of computerized cognitive skills training over a 12 week duration. 7 patients were assigned to cognitive remediation therapy or CRT Group.
Other Names:
  • CRT Group
  • No Intervention: Control Group

    4 patients were assigned to Control group or no cognitive remediation therapy.

    Outcome Measures

    Primary Outcome Measures

    1. Brain activation changes after stimulation with a neurocognitive task in the dorso-lateral prefrontal cortex (DLPFC) [12 weeks]

    Secondary Outcome Measures

    1. Examine the relationship of changes in DLPFC activation patterns in relation to improvement on neurocognitive tests [12 weeks]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 55 Years
    Sexes Eligible for Study:
    Male
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Inpatient status

    • Age 18 - 55

    • Male gender (females are enrolled but will not be scanned)

    • DSM-IV diagnosis of schizophrenia (all subtypes) and schizoaffective disorder

    • illness duration > 5 years

    • MMSE score > 24 (inclusive) at screening

    • Stable dose of oral atypical antipsychotic for at least 4 weeks prior to study entry

    • Total PANSS score > 60 at screening

    • Capacity and willingness to give written informed consent

    • Patients deemed not ready to be discharged within the next 12 weeks

    Exclusion Criteria:
    • Inability to read or speak English

    • Documented disease of the central nervous system

    • History of intellectual impairment pre-dating onset of symptoms of psychosis (e.g. mental retardation)

    • Clinically significant or unstable cardiovascular, renal, hepatic, gastrointestinal, pulmonary, or hematological conditions; HIV positive

    • Any medical condition rendering the subject unable to receive an fMRI scan

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Manhattan Psychiatric Center New York New York United States 10035

    Sponsors and Collaborators

    • Manhattan Psychiatric Center
    • Nathan Kline Institute for Psychiatric Research

    Investigators

    • Principal Investigator: Saurabh Kaushik, MD, Manhattan Psychaitric Center
    • Study Chair: Jean-Pierre Lindenmayer, MD, Manhattan Psychiatric Center
    • Study Chair: Susan McGurk, PhD, Dartmouth College, Hanover
    • Study Chair: Craig A. Branch, PhD, Center for Advanced Brain Imaging, NKI

    Study Documents (Full-Text)

    None provided.

    More Information

    Additional Information:

    Publications

    Responsible Party:
    Jean-Pierre Lindenmayer, Clinical Director, Manhattan Psychiatric Center
    ClinicalTrials.gov Identifier:
    NCT00431223
    Other Study ID Numbers:
    • 05I/C52
    First Posted:
    Feb 5, 2007
    Last Update Posted:
    Oct 6, 2020
    Last Verified:
    Oct 1, 2020
    Keywords provided by Jean-Pierre Lindenmayer, Clinical Director, Manhattan Psychiatric Center
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Oct 6, 2020